Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives

Immunotherapy using chimeric antigen receptor (CAR)-engineered T-cells has achieved unprecedented efficacy in selected hematological cancers. However, solid tumors such as lung cancer impose several additional challenges to the attainment of clinical success using this emerging therapeutic modality....

Descripción completa

Detalles Bibliográficos
Autor principal: Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327905/
https://www.ncbi.nlm.nih.gov/pubmed/37425981
http://dx.doi.org/10.2147/OTT.S341179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327905/
https://www.ncbi.nlm.nih.gov/pubmed/37425981
http://dx.doi.org/10.2147/OTT.S341179

Ejemplares similares